Cargando…

Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus–Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy

BACKGROUND: Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World Health Organization–recommended standard of care in resource-limited settings, but the mechanism of CPT’s beneficial effects is unclear. The COSTOP trial (ISRCTN44723643) evaluated the nonin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kyosiimire-Lugemwa, Jacqueline, Anywaine, Zacchaeus, Abaasa, Andrew, Levin, Jonathan, Gombe, Ben, Musinguzi, Kenneth, Kaleebu, Pontiano, Grosskurth, Heiner, Munderi, Paula, Pala, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336573/ https://www.ncbi.nlm.nih.gov/pubmed/31714954 http://dx.doi.org/10.1093/infdis/jiz494

Ejemplares similares

Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design
por: Anywaine, Zacchaeus, et al.
Publicado: (2015)

Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2018)

Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda
por: Nunn, Andrew, et al.
Publicado: (2016)

Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study
por: Kasirye, Ronnie P., et al.
Publicado: (2016)

Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study
por: Kasirye, Ronnie, et al.
Publicado: (2016)

Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults
por: Kasirye, Ronnie P., et al.
Publicado: (2017)

HIV specific Th1 responses are altered in Ugandans with HIV and Schistosoma mansoni coinfection
por: Obuku, Andrew Ekii, et al.
Publicado: (2023)

Reasons for participating in a randomised clinical trial: The volunteers' voices in the COSTOP trial in Uganda
por: Ssali, Agnes, et al.
Publicado: (2017)

CD8(+) T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4(+) T Cells <200 Cell/μL: The DART Trial STI Substudy
por: Serwanga, Jennifer, et al.
Publicado: (2011)

Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa*
por: Kasirye, R, et al.
Publicado: (2015)

Host HLA B*Allele-Associated Multi-Clade Gag T-Cell Recognition Correlates with Slow HIV-1 Disease Progression in Antiretroviral Therapy-Naïve Ugandans
por: Serwanga, Jennifer, et al.
Publicado: (2009)

The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis
por: Salome, Tino, et al.
Publicado: (2016)

Cardiometabolic risk among HIV-POSITIVE Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy
por: Kazooba, Patrick, et al.
Publicado: (2017)

Coreceptor and Cytokine Concentrations May Not Explain Differences in Disease Progression Observed in HIV-1 Clade A and D Infected Ugandans
por: Wright, Edward, et al.
Publicado: (2011)

Clinical, metabolic, and immunological characterisation of adult Ugandan patients with new-onset diabetes and low vitamin D status
por: Kibirige, Davis, et al.
Publicado: (2022)

P16-16. Gag and Nef specific T-cell responses in HIV-1 infected long-term non-progressors in Uganda
por: Kyosiimire-Lugemwa, J, et al.
Publicado: (2009)

Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2019)

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults
por: Namakoola, Ivan, et al.
Publicado: (2016)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

Readiness of Ugandan health services for the management of outpatients with chronic diseases
por: Katende, David, et al.
Publicado: (2015)

Programmed Death-1(PD-1), a correlate of protection against disease progression in HIV-1 infected long-term non-progressors
por: Kyosiimire-Lugemwa, J
Publicado: (2012)

Computational MHC-I epitope predictor identifies 95% of experimentally mapped HIV-1 clade A and D epitopes in a Ugandan cohort
por: Bugembe, Daniel Lule, et al.
Publicado: (2020)

Vaccination against SARS-CoV-2 in a rural Ugandan population
por: Mugisha, Joseph, et al.
Publicado: (2023)

Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis
por: Kitonsa, Jonathan, et al.
Publicado: (2021)

Effect of Schistosoma mansoni Infection on Innate and HIV-1-Specific T-Cell Immune Responses in HIV-1-Infected Ugandan Fisher Folk
por: Obuku, Andrew Ekii, et al.
Publicado: (2016)

Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2020)

Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda
por: Abaasa, Andrew, et al.
Publicado: (2017)

Drug-related pellagra in a Ugandan woman on isoniazid preventative therapy
por: Coates, Sarah J., et al.
Publicado: (2020)

Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China
por: Cheng, Wei, et al.
Publicado: (2015)

COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort
por: Mayanja, Billy Nsubuga, et al.
Publicado: (2017)

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2020)

Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy
por: Serwanga, Jennifer, et al.
Publicado: (2023)

Combined Silymarin and Cotrimoxazole Therapy Attenuates Pulmonary Fibrosis in Experimental Paracoccidioidomycosis
por: Resende, Victor Quinholes, et al.
Publicado: (2022)

Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial
por: Prentice, Sarah, et al.
Publicado: (2015)

Effect of the “universal test and treat” policy on the characteristics of persons registering for HIV care and initiating antiretroviral therapy in Uganda
por: Mugenyi, Levicatus, et al.
Publicado: (2023)

Correction to: Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial
por: Prentice, Sarah, et al.
Publicado: (2020)

Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
por: Abaasa, Andrew, et al.
Publicado: (2013)

Metronidazole or Cotrimoxazole Therapy Is Associated with a Decrease in Intestinal Bioavailability of Common Antiretroviral Drugs
por: Dossou-Yovo, Flore, et al.
Publicado: (2014)

Clinical and Bronchoscopic Findings in Ugandans with Pulmonary Kaposi's Sarcoma
por: Yoo, Deok Jong, et al.
Publicado: (2005)

Successful treatment of cerebral toxoplasmosis with cotrimoxazole
por: Patil, Harsha V., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_03kq4r6en1bnlnaie9179ib0oe